SCHEMBL70233

SCHEMBL70233

COC(=O)c1ccc(C(=O)OC)c(Br)c1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 13/20 0.62
ALDH1A1 P00352 10/20 0.62
HSD17B10 Q99714 6/20 0.62
HPGD P15428 5/20 0.62
MAPT P10636 4/20 0.62
ATM Q13315 3/20 0.62
GLA P06280 2/20 0.62
GAA P10253 2/20 0.62
CASP1 P29466 1/20 0.62
CASP7 P55210 1/20 0.62
NOTUM Q6P988 1/20 0.60
SMN1; SMN2 Q16637 2/20 0.54
CA12 O43570 3/20 0.53
CA1 P00915 3/20 0.53
CA2 P00918 3/20 0.53
CA7 P43166 3/20 0.53
CA9 Q16790 3/20 0.53
CA14 Q9ULX7 3/20 0.53
XDH P47989 1/20 0.53
KMT2A Q03164 2/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3121267 0.89 HSD17B10 (0.52) KDM4EALDH1A1HSD17B10HPGDMAPT
SCHEMBL29606243 0.89 KDM4E (0.50) KDM4EALDH1A1HSD17B10HPGDMAPT
SCHEMBL16950448 0.89 KDM4E (0.50) KDM4EALDH1A1HSD17B10HPGDMAPT
SCHEMBL1483525 0.89 KDM4E (0.50) KDM4EALDH1A1HSD17B10HPGDMAPT
SCHEMBL17888585 0.89 NOTUM (0.57) KDM4EALDH1A1HSD17B10HPGDMAPT
SCHEMBL28058610 0.89 NOTUM (0.57) KDM4EALDH1A1HSD17B10HPGDMAPT
SCHEMBL5089887 0.87 KDM4E (0.49) KDM4EALDH1A1HSD17B10HPGDMAPT
SCHEMBL14958355 0.87 KDM4E (0.53) KDM4EALDH1A1HSD17B10HPGDMAPT
SCHEMBL2427491 0.87 KDM4E (0.57) KDM4EALDH1A1HSD17B10HPGDMAPT
SCHEMBL16869883 0.86 KDM4E (0.47) KDM4EALDH1A1HSD17B10HPGDMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 201 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4651988-A1 METHODS OF MAKING METAL-ORGANIC FRAMEWORKS WITH PRE-LIGANDS ExxonMobil Technology and Engineering Company (US) 2025-11-26 EP claimed
US-20240300983-A1 Method of Making Metal-Organic Frameworks With a Precursor and Crystallization Aid EXXONMOBIL TECHNOLOGY & ENGINEERING COMPANY (US) 2024-09-12 US claimed
US-20240254148-A1 METHODS OF MAKING METAL-ORGANIC FRAMEWORKS WITH PRE-LIGANDS EXXONMOBIL TECHNOLOGY & ENGINEERING COMPANY (US) 2024-08-01 US claimed
WO-2024155562-A1 METHODS OF MAKING METAL-ORGANIC FRAMEWORKS WITH PRE-LIGANDS ExxonMobil Technology and Engineering Company (US) 2024-07-25 WO claimed
EP-4363100-A1 METHOD OF MAKING METAL-ORGANIC FRAMEWORKS WITH A PRECURSOR AND CRYSTALLIZATION AID ExxonMobil Technology and Engineering Company (US) 2024-05-08 EP claimed
WO-2023278248-A1 METHOD OF MAKING METAL-ORGANIC FRAMEWORKS WITH A PRECURSOR AND CRYSTALLIZATION AID ExxonMobil Technology and Engineering Company (US) 2023-01-05 WO claimed
CN-112592361-B Fluoroboropyrrole functionalized metal organic framework material and preparation method and application thereof 江苏大学 2022-05-20 CN claimed
CN-112592361-A Fluoroboropyrrole functionalized metal organic framework material and preparation method and application thereof 江苏大学 2021-04-02 CN claimed
CN-106432898-B A kind of high barrier composite membrane 苍南县宝丰印业有限公司 2019-01-15 CN claimed
JP-11279123-A None JP disclosed
EP-4081521-B1 SUBSTITUTED TRICYCLIC COMPOUNDS LUPIN LTD (IN) 2025-12-10 EP disclosed
EP-4651988-A1 METHODS OF MAKING METAL-ORGANIC FRAMEWORKS WITH PRE-LIGANDS ExxonMobil Technology and Engineering Company (US) 2025-11-26 EP disclosed
US-20250346585-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS ALEXION PHARMACEUTICALS, INC. (US) 2025-11-13 US disclosed
US-20240300983-A1 Method of Making Metal-Organic Frameworks With a Precursor and Crystallization Aid EXXONMOBIL TECHNOLOGY & ENGINEERING COMPANY (US) 2024-09-12 US disclosed
CN-1092776-A 2-(9-Fluorenone base) carbapeneme intermediate MERCK & CO INC (US) 1994-09-28 CN disclosed
US-5144028-A Antibiotics MERCK & CO., INC. (US) 1992-09-01 US disclosed
EP-0472306-A1 2-(9-fluorenonyl)-carbapenem antibacterial agents MERCK & CO. INC. (US) 1992-02-26 EP disclosed
EP-0469844-A1 2-(9-fluorenonyl)-carbapenem MERCK & CO. INC. (US) 1992-02-05 EP disclosed
US-5034384-A Bactericides, antibiotics for resistant bacteria MERCK & CO., INC. (US) 1991-07-23 US disclosed
US-5025007-A 2-(9-fluorenonyl)-carbapenem antibacterial agents MERCK & CO., INC. (US) 1991-06-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250346585-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS C5, C1S, C9 KDM4E 4647/4885ALDH1A1 1707/4885HSD17B10 2484/4885
US-20240254148-A1 METHODS OF MAKING METAL-ORGANIC FRAMEWORKS WITH PRE-LIGANDS HCAR3, POF1B, HCAR1 KDM4E 3465/4885ALDH1A1 363/4885HSD17B10 280/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.